esketamine + PRF

Esketamine + PRF is a combination therapy involving the administration of esketamine, an NMDA receptor antagonist, together with pulsed radiofrequency (PRF) treatment. Esketamine is primarily known for its rapid-acting antidepressant effects in treatment-resistant depression and acts by antagonizing the N-methyl-D-aspartate (NMDA) receptor on glutamatergic neurons. PRF refers to pulsed radiofrequency neuromodulation, a non-pharmacological intervention that delivers short bursts of high-frequency electrical current to neural tissue—commonly used for pain management by modulating nerve activity without causing significant tissue destruction. This combination has been studied for synergistic analgesic effects, particularly in conditions such as postherpetic neuralgia[1]. The rationale is that esketamine may enhance pain relief when combined with neuromodulatory interventions like PRF.